Brasilia, July 23: Bharat Biotech has terminated a memorandum of understanding to promote its COVID-19 vaccine Covaxin to Brazil’s Precisa Medicamentos, the Indian firm stated on Friday with out disclosing the rationale.
“The Company has terminated the stated MOU with rapid impact. Notwithstanding such termination, Bharat Biotech will proceed to work diligently with ANVISA, the Brazilian drug regulatory physique to full the regulatory approval course of for Covaxin,” it stated.
Bharat Biotech is pursuing approvals in varied international locations as per authorized necessities relevant in every nation, it stated.
Bharat Biotech signed a MoU with Precisa Medicamentos and Envixia Pharmaceuticals LL.C on November 20 for the aim of introducing Covaxin within the territory of Brazil.